Aggression as psychiatric side effect of newer AEDs in patients with epilepsy: Cross-sectional study based on Buss-Perry Aggression Questionnaire
- PMID: 33444989
- DOI: 10.1016/j.yebeh.2020.107546
Aggression as psychiatric side effect of newer AEDs in patients with epilepsy: Cross-sectional study based on Buss-Perry Aggression Questionnaire
Abstract
Purpose: Aggression-irritability is the most commonly encountered antiepileptic-drug-induced psychiatric adverse effects. In this cross-sectional study, we tried to assess antiepileptic-drug-induced aggression in patients with epilepsy (PWE) with a standardized rating scale.
Methods: Two hundred sixty-six consecutive outpatients receiving treatment for epilepsy with antiepileptic drugs (AEDs) were initially examined, and the effects of the investigated drugs in regard to aggression were investigated using the Buss-Perry Aggression Questionnaire (BAQ). We compared BAQ scores as a function of a specific class of AEDs, levetiracetam (LEV), lacosamaide (LCM), perampanel (PER), and carbamazepine (CBZ), and determined whether AED type had a relationship with aggression. Additionally, the association of BAQ score with other clinico-demographic variables was also assessed.
Results: One-way ANOVA revealed that the LEV group had a significantly higher mean BAQ score as compared to the CBZ (P = 0.001) and LCM (P = 0.029) groups for total score. In subscale analysis, the LEV group had higher scores than the CBZ group for the physical aggression (p = 0.01), verbal aggression (p = 0.02) and hostility (p = 0.01) subscales, while the LEV group had a significantly higher mean score than the LCM group for hostility (p = 0.025). In multiple regression analysis, LEV had a statistically significant impact on increased total BAQ score (B = 0.119, p = 0.049). In contrast, CBZ (B = -0.191, p = 0.002), older age at epilepsy onset (B = -0.269, p = 0.000) and female gender (B = -0.210, p = 0.000) had a significant association with lower total BAQ score.
Conclusions: Our results indicate that LEV is associated with increased aggression, while CBZ and LCM showed effects to reduce aggression.
Keywords: AED; Aggression; Epilepsy; Levetiracetam; Perampanel; Psychiatric side effect.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interests Dr. Kousuke Kanemoto has received speaker’s fees from Esai, Daiichi-Sankyo, UCB Japan, and Otsuka Pharmaceutical Company.
Similar articles
-
Differences in aggression as psychiatric side effect of levetiracetam and perampanel in patients with epilepsy.Epilepsy Behav. 2022 Jan;126:108493. doi: 10.1016/j.yebeh.2021.108493. Epub 2021 Dec 18. Epilepsy Behav. 2022. PMID: 34933187
-
Assessment of psychiatric and behavioral adverse effects of antiepileptic drugs monotherapy: Could they have a neuroendocrine correlation in persons with epilepsy?Epilepsy Behav. 2019 Nov;100(Pt A):106439. doi: 10.1016/j.yebeh.2019.07.040. Epub 2019 Sep 28. Epilepsy Behav. 2019. PMID: 31574428
-
The effect of perampanel on aggression and depression in patients with epilepsy: A short-term prospective study.Seizure. 2019 Apr;67:1-4. doi: 10.1016/j.seizure.2019.02.009. Epub 2019 Feb 21. Seizure. 2019. PMID: 30826629
-
Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy.Epilepsy Behav. 2017 Nov;76:24-31. doi: 10.1016/j.yebeh.2017.08.039. Epub 2017 Sep 18. Epilepsy Behav. 2017. PMID: 28931473 Review.
-
Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel.Behav Neurol. 2018 Nov 15;2018:2064027. doi: 10.1155/2018/2064027. eCollection 2018. Behav Neurol. 2018. PMID: 30581496 Free PMC article. Review.
Cited by
-
The association of polytherapy and psychiatric comorbidity in epilepsy.Epilepsy Behav. 2025 Feb;163:110215. doi: 10.1016/j.yebeh.2024.110215. Epub 2024 Dec 12. Epilepsy Behav. 2025. PMID: 39671739 Free PMC article.
-
Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open-label, randomized study.CNS Neurosci Ther. 2022 Jul;28(7):1072-1080. doi: 10.1111/cns.13840. Epub 2022 Apr 15. CNS Neurosci Ther. 2022. PMID: 35429132 Free PMC article. Clinical Trial.
-
Comorbidity of attention deficit hyperactivity disorder in a patient with epilepsy: Staring down the challenge of inattention versus nonconvulsive seizures.Epilepsy Behav Rep. 2024 Feb 1;25:100651. doi: 10.1016/j.ebr.2024.100651. eCollection 2024. Epilepsy Behav Rep. 2024. PMID: 38357032 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical